



Adult CIRB - Early Phase Emphasis Meeting Agenda

April 21, 2026

I Amendment

10509, A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma, Breast Cancer and Other Solid Tumors (Version Date 03/07/26)

II Continuing Review

10371, A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response (Version Date 10/24/24)
